Motl Robert W, Mullen Sean, McAuley Edward
University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Neurol Res. 2012 Mar;34(2):149-52. doi: 10.1179/1743132811Y.0000000063. Epub 2012 Jan 13.
One primary assumption underlying the interpretation of composite multiple sclerosis walking scale-12 (MSWS-12) scores across levels of disability status is multi-group measurement invariance. This assumption was tested in the present study between samples that differed in self-reported disability status.
Participants (n = 867) completed a battery of questionnaires that included the MSWS-12 and patient-determined disease step (PDDS) scale. The multi-group invariance was tested between samples that had PDDS scores of ≤2 (i.e. no mobility limitation; n = 470) and PDDS scores ≥3 (onset of mobility limitation; n = 397) using Mplus 6·0.
The omnibus test of equal covariance matrices indicated that the MSWS-12 was not invariant between the two samples that differed in disability status. The source of non-invariance occurred with the initial equivalence test of the factor structure itself.
We provide evidence that questions the unambiguous interpretation of scores from the MSWS-12 as a measure of walking impairment between samples of persons with multiple sclerosis who differ in disability status.
在解释不同残疾状态水平下的复合性多发性硬化步行量表-12(MSWS-12)得分时,一个主要假设是多组测量不变性。本研究在自我报告的残疾状态不同的样本之间对这一假设进行了检验。
参与者(n = 867)完成了一系列问卷,包括MSWS-12和患者确定的疾病阶段(PDDS)量表。使用Mplus 6·0在PDDS得分≤2(即无行动能力限制;n = 470)和PDDS得分≥3(行动能力限制开始;n = 397)的样本之间检验多组不变性。
对等协方差矩阵的综合检验表明,MSWS-12在残疾状态不同的两个样本之间不是不变的。非不变性的来源出现在因子结构本身的初始等效性检验中。
我们提供的证据对将MSWS-12得分作为不同残疾状态的多发性硬化症患者样本之间步行障碍测量指标的明确解释提出了质疑。